Severe influenza treatment guideline

Choi, Won Suk; Baek, Ji Hyeon; Seo, Yu Bin; Kee, Sae Yoon; Jeong, Hye Won; Lee, Hee Young; Eun, Byung Wook; Choo, Eun Ju; Jacob, Louis; Kim, Young Keun; Song, Joon Young; Wie, Seong Heon; Lee, Jin Soo; Cheong, Hee Jin

doi:10.3904/kjim.2014.29.1.132

Cited by 24 publications

(21 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although levels of C-reactive protein and procalcitonin are useful for differential diagnosis accompanying bacterial infections, current influenza guidelines recommend that clinicians should treat all influenza-related pneumonia cases with antibiotics. 10,11 Secondary bacterial pneumonia usually develops 1-2 weeks after influenza-like illness following a brief period of improvement. Patients with secondary bacterial pneumonia show typical symptoms and signs of bacterial pneumonia (fever, chill, cough, purulent sputum, dyspnea) with a case fatality rate of about 7%.…”

Section: Introductionmentioning

confidence: 99%

Effects of influenza immunization on pneumonia in the elderly

Heo

Song

Noh³

et al. 2017

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Influenza virus is a common pathogen implicated in respiratory tract infections, annually affecting up to 20% of the general population, and pneumonia is a leading cause of death after influenza infection. Post-influenza pneumonia is especially common in the elderly and chronically ill patients. The risk of post-influenza pneumonia is significantly increased according to the number of concurrent comorbidities. Vaccination is the primary measure used to abate influenza epidemics and associated complications. In meta-analyses, influenza vaccine significantly reduces pneumonia- and influenza-related hospitalizations, with a vaccine effectiveness of 25-53%. However, considering the poor effectiveness of conventional influenza vaccines in the elderly, several highly immunogenic influenza vaccines have been developed. Further evaluations of the comparative effectiveness of diverse vaccine formulations are warranted to assess their utility for preventing influenza infection, post-influenza pneumonia, and related hospitalization/mortality. Based on cost-effectiveness and budget impact analysis, influenza vaccination strategies should be tailored in the elderly.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of influenza immunization on pneumonia in the elderly

Heo

Song

Noh³

et al. 2017

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Severe influenza is defined as influenza infection accompanied by complications that require hospitalisation, and is attributed to over 3.4% of all critical hospitalisations during influenza season 1 . Current treatment for severe influenza generally incorporates supportive care and antiviral medications such as oseltamivir (Tamiflu TM ) or zanamivir (Relenza TM ) 5 , however viral resistance to such medications is increasing, and is most often acquired by infective viruses during hospitalisation and treatment 6 , which is a significant risk for immunocompromised patients hospitalised for extended durations 7 .…”

mentioning

confidence: 99%

“…Despite clinical efficacy, the use of human-derived Ab therapies have significant logistical challenges including lengthy time periods for identification and screening of potential serum donors, and validation of sera and subsequent Ab products 19 . Consequently, current guidelines do not recommend IVIG or convalescent sera as a therapy for severe influenza 5 . Alternatively, passive immunotherapies utilising humanised monoclonal Abs (mAbs) have been developed for influenza prophylaxis and treatment, and whilst mAbs targeting HA have potent neutralising capacity, they are often not cross-reactive against multiple strains and may prompt the development of resistant mutants 20 .…”

mentioning

confidence: 99%

Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection

Stevens

Hatjopolous

Fraser

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Passive immunotherapy may have particular benefits for the treatment of severe influenza infection in at-risk populations, however little is known of the impact of passive immunotherapy on the formation of memory responses to the virus. Ideally, passive immunotherapy should attenuate the severity of infection while still allowing the formation of adaptive responses to confer protection from future exposure. In this study, we sought to determine if administration of influenza-specific ovine polyclonal antibodies could inhibit adaptive immune responses in a murine model of lethal influenza infection. Ovine polyclonal antibodies generated against recombinant PR8 (H1N1) hemagglutinin exhibited potent prophylactic capacity and reduced lethality in an established influenza infection, particularly when administered intranasally. Surviving mice were also protected against reinfection and generated normal antibody and cytotoxic T lymphocyte responses to the virus. The longevity of ovine polyclonal antibodies was explored with a half-life of over two weeks following a single antibody administration. These findings support the development of an ovine passive polyclonal antibody therapy for treatment of severe influenza infection which does not affect the formation of subsequent acquired immunity to the virus.

show abstract

“…S. aureus and S. pneumoniae infections are commonly followed by influenza infection. Therefore, patients with influenza LRTIs should be administered antibiotics to which these bacteria are susceptible [ 144 ]. As it is not possible to distinguish these bacteria from other co-pathogens (i.e., PCP, CMV, or fungi, etc.)…”

Section: Common Respiratory Virusesmentioning

confidence: 99%

Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea

Cho

Lee

2018

Korean J Intern Med

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is a treatment for hematologic malignancies, immune deficiencies, or genetic diseases, ect. Recently, the number of HSCTs performed in Korea has increased and the outcomes have improved. However, infectious complications account for most of the morbidity and mortality after HSCT. Post-HSCT infectious complications are usually classified according to the time after HSCT: pre-engraftment, immediate post-engraftment, and late post-engraftment period. In addition, the types and risk factors of infectious complications differ according to the stem cell source, donor type, conditioning intensity, region, prophylaxis strategy, and comorbidities, such as graft-versushost disease and invasive fungal infection. In this review, we summarize infectious complications after HSCT, focusing on the Korean perspectives.

show abstract

Severe influenza treatment guideline

Cited by 24 publications

References 76 publications

Effects of influenza immunization on pneumonia in the elderly

Effects of influenza immunization on pneumonia in the elderly

Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection

Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea

Contact Info

Product

Resources

About